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1. Introduction  
The key intrinsic cell of the glomerulus is the podocyte, which is described as the “organiser 
and caretaker” of glomerular structure and function (Leeuwis et al., 2010). Podocytes (also 
known as visceral epithelial cells) are terminally differentiated pericyte-like epithelial cells 
that form the outer exocapillary layer of the glomerular filtration barrier. They have a critical 
function in maintaining normal glomerular capillary permeability and functional integrity 
(Marshall and Shankland, 2007). The aim of this chapter is to summarize the current 
research on the contribution of podocytes to the disease process in glomerulonephritis in 
connection to the mTOR signaling pathway. 
During glomerular development, the podocyte has a central role in integrating signals from 
the other glomerular resident cells to form the proper basic structure of the glomerular 
filtration unit (Eremina and Quaggin, 2004). Podocytes line the outer aspect of the glomerular 
basement membrane (GBM) and physiologically have a unique and complex cytostructure 
consisting of three morphologically and functionally distinct segments: a cell body, foot 
processes and the slit diaphragm (Mundel and Kriz, 1995). Major processes arise from the cell 
body and split into foot processes. The foot processes contain an actin-based cytoskeleton that 
is linked to the glomerular basement membrane at focal contacts (Faul et al., 2007). Podocyte 
foot processes form a highly branched interdigitating network which  enwrap the glomerular 
capillaries, and are connected by the slit diaphragm. Three distinct membrane compartments 
form the foot processes: the basal side, the apical side, and the slit filtration diaphragm. The 
basal side connects the podocyte to the GBM with several types of integrins and dystroglycans 
(Pavenstadt et al., 2003). It also plays a role in endocytosis of albumin and IgG trapped in the 
GBM, offering possibilities for drug delivery (Eyre J, 2007) (Akilesh S, 2008). The apical side 
contains negatively charged proteins such as podocalyxin, a sialoglycoprotein, and 
podoplanin which form a glycocalyx layer and thereby contribute to charge-selectivity of the 
glomerular filtrate (Koop et al., 2008) (Orlando RA, 2001) (Kerjaschki D, 1984). 
The slit diaphragm is the most complex layer of the glomerular filtration barrier, with a 
constant width of 40 nm (Tryggvason et al., 2006, Benzing, 2004).  The main function of the slit 
diaphragm is to form a size-selective barrier for proteins and since many of the slit diaphragm 
proteins are phosphorylated, this contributes to the charge-selective element (Tryggvason K, 
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2001). Podocyte-specific multiprotein complexes, similar to adherens junctions, extend 
between the filtration slits, closely interact with the actin cytoskeleton, influencing signaling 
pathways and motility of the podocyte (Lee et al., 2009) (Burt et al., 2007) and thereby 
establishing the final barrier to urinary protein loss (Somlo and Mundel, 2000). 
The proteins which make up the slit diaphragm system are nephrin, Neph1, Neph2, 
podocin, fatty acid transporter tumor suppressor homolog-1 (FAT1) and FAT2, and the 
calcium channel transient receptor potential cation 6 (TRPC6) and cadherins (Harita Y, 
2008) (Yaoita et al., 2005) (Liu G, 2003) (Dryer SE, 2010) . Linker proteins such as CD2-
associated protein (CD2AP), and Nck connect the slit diaphragm to the actin skeleton 
(Coward et al., 2005) (Jones et al., 2009). Also, proteins that are directly part of the slit 
diaphragm but are involved in regulating the actin cyskeleton include synaptopodin, the 
GTPase dynamin and cytoplasmic Cathepsin L (CatL) (Sever S, 2007). Nephrin, a member 
of the immunoglobulin family, is regarded as the critical structural component of the slit 
diaphragm of podocytes as it is composed of an extracellular and intracellular domain 
capable of transducing signals between neighboring podocytes, and is the protein that 
bridges the distance between interdigitating foot processes (Zhu et al., 2008). Encoded by 
the NPHSI gene, both humans and experimental mice models lacking nephrin or a 
mutation in the NPHSI gene are born without typical slit diaphragms and exhibit severe 
podocyte abnormalities and massive proteinuria in utero and at birth (Kuusniemi et al., 
2006). The Src family kinase Fyn, controls the phosphorylation of nephrin and when 
phosphorylated together with CD2AP and podocin, phosphoinositide-3-OH kinase 
(PI3K)-dependent Akt activation is induced, which is thought to inhibit podocyte 
apoptosis (Huber et al., 2003). Phosphorylation of nephrin also promotes Nck-dependent 
actin rearrangements, indicating an important role for nephrin in preventing foot process 
effacement (Verma et al. 2006). The transmembrane proteins Neph1 and Neph2 are 
structurally related to nephrin, containing extracellular IgG-like motifs, and interact with 
nephrin during intracellular signaling. FAT1 and FAT2, like Neph1 and Neph2, are part of 
the slit diaphragm but contain cadherin-like repeats (Tryggvason et al., 2006). Podocin is a 
membrane-associated intracellular protein, and is involved in the organization of the slit 
diaphragm complex, interacting with both nephrin and CD2AP (Schwarz et al., 2001). 
CD2AP is linked to nephrin, podocin and the actin cytoskeleton, transducing signals to 
the actin cytoskeleton. Recently, attention has focused on TRPC6, a calcium channel 
present in the slit diaphragm complex interacting with both nephrin and podocin, and 
involved in podocyte mechanosensation and regulation of gene transcription (Moller et 
al., 2009). Synaptopodin, an actin-binding protein, is present in the foot process and 
involved in actin elongation through ┙-actinin-4 by modulating RhoA signaling 
(Asanuma et al., 2005) (Asanuma et al., 2006). The GTPase dynamin is also involved in 
actin modulation, and both GTP-bound dynamin and unphosphorylated synaptopodin 
are direct targets of the proteolytic activity of the cysteine protease Cathepsin L (Reiser et 
al., 2004). Undoubtedly, an intricate alignment of the slit diaphragm proteins is pivotal for 
proper filtration and renal function and disruption to the expression or function of these 
proteins alters the intercellular junctions and cytoskeletal structures of the foot processes 
and the cell takes on an effaced phenotype, pathologically known as effacement. Thus, 
foot processes effacement is identified as the hallmark in the development of proteinuric 
kidney disease (Kwoh et al., 2006) (Perysinaki GS, 2011). 
As well as having the role of maintaining glomerular structural and functional integrity, 
podocytes also play a key role in autocrine signalling. Podocytes are essential suppliers of 
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vascular endothelial growth factor A (VEGF-A) to the glomerular capillary endothelium and 
with glomerular endothelial cells, they are among the few cell types where VEGF-A is 
expressed throughout life (Tufro et al., 1999) (Simon et al., 1995). In addition, injured 
podocytes have been reported to upregulate expression of the transmembrane protein B7-1 
(or CD80) on their surface, normally expressed on B cells and other antigen-presenting cells 
(Reiser J, 2004). To illustrate, in response to B7-1 activation due to binding of LPS to toll-like 
receptor-4 (TLR4), the podocyte slit diaphragm is rearranged leading to proteinuria, a 
response not seen in B7-1 knockout mice (Reiser J, 2004),  suggesting that the podocyte is 
part of the innate immune system and has a role in danger signaling (Reiser J, 2004) 
(D'Agati, 2008). 
Clearly, the podocyte is a highly complex cell involved in maintaining normal capillary health, 
other glomerular cells and structures as well as being a gateway for the perm-selectivity of the 
glomerular filtrate. Given the terminally differentiated nature of podocytes, loss of these cells 
cannot be compensated by regenerative proliferation. Thus an intricate alignment of the slit 
diaphragm proteins is pivotal for proper filtration and renal function. Hence, podocytes are 
key contributors to glomerular disease and understanding the cellular mechanisms governing 
their response to injury is imperative to the development of therapeutic strategies to directly 
protect podocytes in disease situations from advancing to kidney sclerosis. 
2. Role of podocytes in glomerular disease 
Glomerular diseases (including diabetic kidney disease) are the most common cause of end-
stage kidney failure throughout the world. They comprise a variety of heterogenous 
disorders that are due to acute or chronic injury of the renal glomeruli. Whether they are a 
primary disease process or a secondary manifestation of a systemic disease process, the 
working paradigm is that they all converge onto few pathways of disease progression.  
Over the last decade, immense knowledge has emerged implicating podocytes as key 
players in a broad range of glomerular diseases. Injury to the podocytes is the initiating 
cause of many renal diseases, leading to proteinuria with possible progression to end-stage 
renal disease (Leeuwis et al., 2010). Human podocytopathies include focal and segmental 
glomerular sclerosis (FSGS), minimal change disease, membranous nephropathy, collapsing 
glomerulopathy and diabetic nephropathy and more recently podocytes have also been in 
implicated in proliferative forms of GN such as crescentic glomerulonephritis (Thorner et 
al., 2008) (Moeller et al., 2004) . The filtration barrier is the major pathogenic site in almost all 
glomerular diseases and its study is therefore of clinical significance. When podocytes are 
injured, as in many forms of glomerulonephritides, the podocytes respond by retracting 
their foot processes into their cell bodies to form flattened dense epithelium, 
morphologically designated foot process effacement (Harita et al., 2006) (Mundel and 
Shankland, 2002). These podocytic changes lead to precipitous protein leakage into the 
urine, which over a chronic period of time culiminates in the development of 
glomerulosclerosis and end-stage kidney failure (Smoyer and Mundel, 1998). Thus, the 
intrinsic defect in the cytoskeletal proteins renders podocytes non-functional as the actin 
cytoskeletal organisation changes from parallel contractile bundles into a dense network, 
culminating in foot processes effacement, subsequent proteinuria and sclerosis.  
Podocyte contribution is essential to the formation of glomerular crescent as they populate 
cellular crescents in human and experimental models of CGN (Thorner et al., 2008) (Bariety 
et al., 2005) (Moeller et al., 2004) (Le Hir et al., 2001). So far, the earliest documentation of 
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podocyte response to injury in a model of crescentic glomerulonephritis is from the 
ultrastructural studies conducted by Le Hir et al., 2001, whereby podocytes formed bridges 
glomerular tuft area and Bowman’s capsule in mice ten days injection with rabbit anti-GBM 
serum (Le Hir et al., 2001). These findings were the first to provide a link between the initial 
inflammatory injury processes occurring within the endocapillary compartment of the 
glomerular tuft and the formation of a multilayered cellular crescent in bowman’s space (Le 
Hir et al., 2001). What causes these presumably terminally differentiated visceral cells to 
acquire a phenotype favourable for cytoskeletal reorganisation leading to contact with the 
parietal basement membrane of Bowman’s capsule, culminating in the formation of 
podocyte bridges is yet to be explored.  
3. The mammalian target of rapamycin complex signal transduction pathway  
The coordinated control of cell growth to produce a genetically predetermined cell size, 
shape, survival and proliferation is greatly influenced by a ubiquitously expressed 
serine/threonine kinase known as the mammalian target of rapamycin (mTOR).  mTOR 
functions to regulate a variety of cellular activites that are sensitive to environmental 
stress (Foster, 2007) (Sabatini, 2006). Our current understanding of mTOR dates back to 
the initial discoverers of its inhibitor, Rapamycin, about three decades ago on the 
Southern Pacific Ocean island named Easter Island, known as “Rapa Nui” by the 
language of its native Polynesian inhabitants (Yang and Guan, 2007). The bacterial strain, 
Streptomyces hygroscopicus, which was first isolated from this island secrete a potent 
anti-fungal macrolide that was named rapamycin after the location of its discovery (Yang 
and Guan, 2007). Rapamycin was initially developed as an anti-fungal agent (Loewith, 
2011). However, its major application quickly developed after rapamycin was proven to 
have immunosuppressive and anti-proliferative properties (Yang and Guan 2007). To 
date, rapamycin (or sirolimus) has become routinely used clinically for 
immunosuppression in organ transplantation, prevention of restenosis post-angioplasty, 
and chemotherapy in a variety of cancers (Dobashi et al., 2009) (Yang and Guan, 2007). 
mTORC1 Signaling pathway: mTOR is the downstream effector protein belonging to the 
phosphatidylinositol (PIKK)-related kinase family with a predicted molecular weight of 
290kDa, and is part of the PI-3 Kinase pathway which is part of the tyrosine kinase 
activation cascade (Vogt, 2001). The physiological importance of the primordial mTOR is 
undoubtedly demonstrated by the fact that the knockout of mTOR in mice is embryonically 
lethal (Gangloff et al., 2004) (Murakami M, 2004).  In mammalian cells, mTOR signaling 
consist of two distinct multiprotein complexes named mTOR Complex-1 (TOR-raptor-G┚L) 
and mTOR Complex-2 (TOR-rictor-G┚L), and each complex is evolutionarily conserved 
from yeast to mammalian eukaryotes with distinct and essential roles in maintenance of cell 
function and structure (Loewith R, 2002).  It is now well established that the raptor-
containing mTOR complex (mTORC1) is rapamycin-sensitive (Sabatini et al., 1994), whereas 
the rictor-containing mTOR complex (mTORC2) is rapamycin-insensitive (Sarbassov et al., 
2006). In contrast to mTORC1, mTORC2 regulates growth factor signalling, cell survival 
(AKT) and cytoskeletal reorganization (Facchinetti et al., 2008) (Bhaskar PT, 2007) (Jacinto et 
al., 2004). However, as much of our current understanding of mTOR is limited to mTORC1, 
because of the availability and wide use of rapamycin. The factors promoting mTORC2 
activation are not well defined and may be controlled by the activation states of multiple 
mTORC1 effector proteins (Gossage L, 2010).  
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Fig. 1. Mammalian target of rapamycin (mTOR) signaling pathway. mTOR incorporates 
growth factor activation from the tyrosine receptor kinase to control several catabolic and 
anabolic processes that collectively determine cell growth and metabolism. mTOR is an 
atypical serine/threonine kinases. In response to growth factors, Akt phosphorylates and 
inactivates TSC1-TSC2, allowing Rheb to activate mTOR. Low energy (cellular energy status) 
inhibits mTORC by activating AMPK, which phosphorylates and activates TSC1-TSC2.  mTOR 
controls protein synthesis by phosphorylating and inactivating the translational inhibitor 
4EBP-1 and by phosphorylating and activating P70S6 kinase. mTORC2 promotes cell survival 
through direct phosphorylation of serine 473 in the hydrophobic motif of AKT. The 
immunosuppressant rapamycin in complex with FKBP inhibits mTOR when bound to raptor.  
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Activities of mTORC1: The mTORC1 arm of mTOR signaling pathway promotes cell cycle 
progression through G1-phase and proliferation through multiple molecular mechanisms. 
mTORC1 signaling functions via the two earliest recognized and best-characterised 
downstream effector proteins namely, SK1 (p70 ribosomal protein S6 kinase 1) and 
eukaryotic initiation factor (eIF) 4E-binding protein 1 (4EBP1) that are involved in the 
regulated control of protein synthesis/ribosome biogenesis and cap-dependent translation 
initiation (Yang and Guan 2007). The pathway is activated as follows: Firstly, mTOR 
incorporates growth factor activation from the tyrosine kinase receptor to activate AKT via 
phosphorylation at the threonine-308 residue site, which results in phosphorylation and 
subsequent inactivation of the endogenous mTOR complexes inhibitors, the tuberous 
sclerosis complexes-1 and 2 (TSC1-TSC2). Upon phosphorylation of TSC1-TSC2 
heterodimer, Rheb is released which positively regulates mTORC1 for activation via 
phosphorylation at the serine 2448 site (Yang and Guan 2007). The activation of mTORC1 
results in increased protein synthesis by phosphorylating and inactivating the translational 
inhibitor 4E-BP and by phosphorylating and activating S6 kinase (S6K). S6K, in addition to 
phosphorylating various translational targets. It also phosphorylates and inhibits insulin 
receptor substrate 1 (IRS-1) as part of a negative feedback loop that attenuates insulin 
signaling. mTORC2 promotes cell survival through direct phosphorylation of serine 473 in 
the hydrophobic motif of AKT. The immunosuppressant rapamycin in complex with FKBP 
binds and inhibits mTOR when bound to raptor.  Activation of the protein kinase p70 S6 
kinase (p70S6k) and subsequent phosphorylation of 40S subunit of the S6 ribosomal protein 
regulates the translation of ribosome proteins and components of the translational 
machinery. mTORC1 also phosphorylates 4E-BP1, which releases it from the translation 
factor, eIF-4E, and allows the latter to initiate translation of messenger RNAs. TORC1 also 
regulates proliferation through modulation of cell cycle regulatory proteins, involving the 
cyclin D1/E-cyclin-dependent kinase (Cdk)-2/4-retinoblastoma pathway (Berthet and 
Kaldis, 2007). In particular, eIF4E regulates the translation of the Cyclin D1 and D3 genes, 
which leads to reduced formation of cyclinD3-cdk4 kinase (Hleb M, 2004). TORC1 activation 
is correlated with the protein expression of cdk2 (Chen et al., 2009) and also increases the 
expression of p27kip1 (the endogenous inhibitor of cdks 2 and 4), through undefined 
mechanisms (Sun et al., 2008) (Wang et al., 2001). mTORC1 is also a negative regulator of 
autophagy (one of the major systems which regulate cellular protein degradation) (Meijer 
and Codogno, 2004).  
The earliest recognized and best-studied mTORC1 downstream effector proteins are SK1 
(p70 ribosomal protein S6 kinase 1) and eukaryotic initiation factor (eIF) 4E-binding protein 
1 (4EBP1). Under basal conditions, S6KI and 4EBP1 are bound to eIF3 and remain inactive 
(Holz MK, 2005) mTOR-dependent phosphorylation of 4EBP1 releases eIF4E, initiating cap-
dependent de novo translation of various species of mRNA (Brunn et al., 1997 and Gingras 
et al., 2004). Another set of downstream effectors of mTOR are the serine/threonine protein 
kinases, S6 kinase 1 (S6K1) and S6 kinase 2 (S6K2), both of which are responsible for 
phosphorylation of the 40S ribosomal protein S6 (rpS6) (Murakami et al., 2004, Sarbassov et 
al., 2004 and Shima et al., 1998). mTOR activation of S6K results in phosphorylation of S6 
ribosomal protein, leading to recruitment of the 40S ribosome subunit and translation of 5'-
terminal oligopyrimidine tract (5'TOP) mRNA (Jefferies et al., 1997). These 5'TOP mRNA 
encode primarily ribosomal proteins and other components of the translational apparatus 
(Meyuhas et al., 2000). Thus, by controlling S6K activity, mTOR also regulates the 
abundance of translational machinery. Under favorable growth conditions, mTOR is 
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activated and S6K and 4E-BP1 are phosphorylated, leading to new RNA and protein 
synthesis. Proliferation of intrinsic glomerular cells, characterized by increased RNA and 
protein synthesis with DNA replication and cell division is fundamental in crescent 
formation in crescentic glomerulonephritis. It may well be that mTOR plays a critical role in 
this disease process. Thus, the judicious attenuation of proliferation with mTOR inhibitors 
may potentially provide an option to limiting the progression of renal injury from 
progressing to crescentic glomerulonephritis. 
4. Implication of mTOR signaling in renal disease  
The availability of the mTOR inhibitor (mTORi) rapamycin, which is used clinically as an 
immunosuppressant drug to prevent rejection in organ transplantation, has helped to 
identify a large signaling network around mTOR signaling leading to extensive studies for 
its effect on cell proliferation and apoptosis not just in cancer but in both human and 
experimental in vivo and in vitro models of glomerular disease.  Nevertheless, whilst some 
studies suggest mTOR inhibition by rapamycin might halt or reverse glomerulopathies  
(Mori H, 2009) (Inoki, 2008) (Lloberas et al., 2006) (Sakaguchi et al., 2006) (Rangan and 
Coombes, 2007) other studies documented an increase in proteinuria and glomerulosclerosis 
in patients and in animal models following rapamycin treatment (Torras J, 2009) (Amer and 
Cosio, 2009) (Munivenkatappa et al., 2010)  (Letavernier et al., 2007), suggesting a 
significance for mTORC1 signaling in endogenous and compensatory regenerative repair of 
renal cells in glomerulopathies. To add, most studies regarding the role of mTOR signaling 
in renal disease are based on pharmacological intervention with rapamycin (and as 
mTORC1 is expressed in resident as well as infiltrating cells) this approach does not allow 
for distinguishing the specific role of blocking mTORC1 in intrinsic renal cells. Furthermore, 
off-target effects have been described with long-standing application of rapamycin, most 
notably the inhibition of mTORC2 (Sarbassov et al., 2006). Therefore, tissue-specific analysis 
of mTOR signaling is required for an in-depth understanding of the functional and cell 
autonomous role of mTOR in diabetic nephropathy and other glomerular diseases.  
5. Role of TORC1 in normal podocyte biology 
The mTOR signalling pathway has emerged as having an important role in maintaining 
podocyte survival and cytoskeletal structure. Recently, elegant studies by Godel et al. and 
Inoki et al., conducted in conditional knockout mice, have comprehensively verified the 
critical role that TORC1 plays in maintaining normal podocyte function and glomerular 
architecture. Godel et al. showed that podocyte-specific deletion of TORC1 (Raptorflox/flox)  
in conditional knockout mice caused heavy proteinuria at 8 weeks of age, associated with 
development of segmental glomerulsclerosis (particulary in juxtamedullary glomeruli), 
reduced expression of slit diaphragm proteins (nephrin, podocin and Par3), foot process 
effacement and increased mortality after 8 months of age. The dependence of normal 
podocyte biology on TORC1 was also determined by genetic background (with 
conditional TORC1 deletion in ICR mice being more prone to proteinuria than those from 
a C57BL/6 background) as well as age (suppression of TORC1 was more resistant in 
causing proteinuria in adult mice). Godel and co-authors also demonstrated that the 
combined inactivation of TORC1 and TORC2 (using Raptor/Rictorpodocyte conditional 
mice) caused a rapid onset of nephrotic syndrome, FSGS, renal failure and death by 8 
weeks of age.  
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Using an alternative approach, Inoki et al. examined the effects of over-activation of TORC1 
in podocytes using podocyte-specific deletion of TSC1 (a negative regulator of TORC1 
activation). These studies showed that high TORC1 activation led to mesangial expansion 
and glomerulosclerosis, proteinuria, podocyte body enlargement and foot process 
effacement and a reduction in podocyte number (partly due to reduced podocyte 
attachment) and death due to renal failure by 14 weeks. The molecular and cellular changes 
underlying these morphological changes included mislocalization of nephrin, cellular 
dedifferentiation and conversion to a fibroblastic phenotype (as determined by increased 
expression of desmin and redistribution of zonula occluden-1) and promoted endoplasmic 
reticulum stress. These effects were rapamycin-sensitive and reversible if attenuated at an 
early stage, but not after prolonged over-activation. Taken together, the studies by Godel et 
al. and Inoki et al. highlight that glomerular TORC1 activity in podocytes must kept under 
low finely regulated levels, with both complete suppression as well as over-expression of 
TORC1 having deleterious effects on podocyte structure and function. 
The molecular mechanisms by which TORC1 regulates normal podocyte function is not yet 
fully understood. Previous in vitro studies investigating the effects of TORC1 inhibition 
with sirolimus in cultured podocytes have shown that the TORC1 regulates at least three 
physiological functions which are essential for normal podocyte surivial as well as 
functioning of the glomerular filtration barrier: (i) podocytes produce VEGF (an important 
angiogenic peptide that maintains the normal integrity of the glomerular-endothelial barrier 
(Eremina, Baelde, & Quaggin, 2007), in a TORC1 dependent manner; (ii) TORC1 may 
regulate pro-survival pathways in podocytes. At present, there is only indirect evidence to 
support this hypothesis. Nephrin and CD2-associated protein (CD2AP) constitutively 
regulate PI3K and Akt, both of which are upstream of TORC1 (Huber et al., 2003). Nephrin 
is a transmembrane protein expressed in podocytes and is linked to the cytoskeleton by 
CD2AP (Pavenstadt, Kriz, & Kretzler, 2003). Both are critical factors that maintain the 
normal function of the slit diaphragm of the podocytes and the glomerular filtration barrier 
(Pavenstadt et al., 2003). Given that mutations in the genes encoding nephrin or CD2AP lead 
to FSGS, these studies raise the possibility that their downstream pathways involve TORC1 
(Kwoh, Shannon, Miner, & Shaw, 2006). This postulate has recently been confirmed in two 
studies showing that sirolimus reduced Akt phosphorylation in cultured podocytes 
(Letavernier et al., 2008; Vollenbroeker et al., 2008). Akt is a cytoplasmic serine/threonine 
kinase that regulates programmed cell death by phosphorylating substrates that regulate 
apoptosis (such as caspase-9, XIAP, MM2); (iii) Lastly, sirolimus altered the cytoskeletal 
structure of podocytes in vitro. The latter may be due to inhibitory effects on Akt, TORC2 
and Wt1(Letavernier et al., 2008; Vollenbroeker et al., 2008). In vitro, podocytes exposed to 
sirolimus (20 ng/ml) for 48 hours developed a more roundshaped morphology with 
reorganization of cytoskeleton and redistribution of actin filaments and focal adhesion 
proteins (viniculin) to the periphery of the cell (Letavernier et al., 2008; Vollenbroeker et al., 
2008). These effects may lead to reduced cell adhesion and migration (Vollenbroeker et al., 
2008). 
6. Role of TORC1 in podocytes in human and animal models of glomerular 
disease 
Glomerular diseases can be classified according to changes in podocyte number and 
differentiation, as proposed by Shankland and colleagues (Griffin et al. 2003)(Figure 2). 
Podocyte number is normal or decreased in minimal change disease, focal segmental 
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glomerulosclerosis and diabetic kidney disease, whereas it is increased with an 
dedifferentiated phenotype in HIV nephropathy, collapsing variant of focal segmental 
glomerulosclerosis and crescentic glomerulonephritis. Loss of Podocytes (due to cell death 
and detachment from the glomerular basement membrane) is a key determinant of 
progression to kidney failure, regardless of the cause. Our knowledge about the role of 
TORC1 in podocytes in glomerular disease is incomplete and is summarised and discussed 
below.  
 
 
Fig. 2. Classification of glomerular diseases according to changes in podocyte number and 
differentiation, as proposed by Shankland and colleagues (Griffin et al. 2006). 
6.1 Glomerular diseases in which podocyte number decreased or normal 
Minimal change disease/focal segmental glomerulosclerosis. Several studies have examined the 
effects of sirolimus in animal models of glomerular diseases associated with heavy 
proteinuria and reduced or normal podocyte number. These models resemble the human 
counterparts of FSGS and minimal change disease. Both everolimus and sirolimus were 
renoprotective when administered during the early stages of non-immune FSGS induced by 
either puromycin (Daniel et al., 2000) or adriamycin (Rangan and Coombes, 2007) in rats. In 
adriamycin nephropathy, commencement of sirolimus during the established, but early 
phase of disease (day 14 to 49), attenuated the increase in kidney weight, glomerular 
capillary tuft enlargement, glomerulosclerosis and tubulointerstitial fibrosis as well as renal 
cortical TGF-┚ (Rangan and Coombes, 2007), whereas interstitial inflammation and 
peritubular myofibroblast accumulation were unaffected. Interestingly, the examination of 
sirolimus on proteinuria and subsequent podocyte damage in two contrasting renal disease 
models, with clearly different pathophysiological mechanisms (a glomerular toxico-
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immunological model induced by puromycin aminonucleoside, and a chronic 
hyperfiltration and inflammatory model by mass reduction), both treated with a fixed high 
sirolimus dose revealed, significant increases in proteinuria, together with a significant fall 
in podocin immunofluorescence, as well as clear additional damage to podocyte foot 
processes (Torras et al., 2009). Conversely, after mass reduction, rapamycin produced lower 
levels of proteinuria and amelioration of inflammatory and pro-fibrotic damage. In contrast 
to the puromycin model, higher glomerular podocin and nephrin expression and 
amelioration of glomerular ultrastructural damage were found (Torras et al., 2009). Thus 
these studies suggest sirolimus has dual opposing effects, with proteinuria and podocyte 
damage aggravation in the glomerular model and a nephro-protective effect in the chronic 
inflammatory tubulointerstitial model. To add, sirolimus has also been reported to damage 
podocytes in rats with protein overload nephropathy (Cia et al., 2011). Collectively these 
findings indicate that sirolimus produces slight alterations in podocyte structure when 
acting on healthy podocytes, but it clearly worsens those podocytes damaged by other 
concomitant injury.  
In humans with FSGS, the role of TORC1 in podocytes in disease pathogenesis has not 
been directly evaluated. Clinical trial evidence however suggests that TORC1 has a 
dichotomous role (congruent with data from TORC1-conditional knockout mice) 
indicating that its role in disease is finely balanced. (Pollak, 2008, Fervenza et al., 2004, 
Tumlin et al., 2006, Cho et al., 2007, Aymanns et al., 2006). In a prospective open label 
trial, conducted by Tumlin and colleagues (Tumlin et al., 2006), sirolimus induced 
complete remission (defined as <300mg protein/24h after 6 months) in 4 of the 21 
patients, and partial remission (defined as a 50% reduction of baseline proteinuria) in 8 of 
the 21 patients tested within the 6 month period. Twelve of the responsive patients, along 
with 2 others who saw a 30% reduction in proteinuria continued sirolimus therapy for 
another 6 months. In these patients, baseline proteinuria fell significantly within the first 6 
months, however this decline in proteinuria became statistically insignificant from the 
period of 6 months to 12 months. Overall, the study found that sirolimus was able to 
stabilize the renal function of patients with FSGS, by not only reducing proteinuria, but 
also glomerular pore size and increasing glomerular ultrafiltration coefficient (Fervenza et 
al., 2004). On the other hand, Patel and colleagues (Patel et al., 2005) reported that a 
combination of tacrolimus with sirolimus was beneficial in reducing proteinuria and 
inducing remission in a patient with a long history of refractory minimal change 
nephropathy. In contrast, other smaller pilot studies in humans highlighted the possible 
nephrotoxic effects of sirolimus in patients with FSGS (Tumlin et al., 2006, Cho et al., 
2007). A common observation amongst all the studies was that a longer duration of 
disease was associated with resistance to sirolimus therapy and a risk for renal 
dysfunction. Therefore, genetic factors, stage of disease and level of TORC1 inhibition 
may be factors underlying these variable results in humans. 
Membranous nephropathy. The effects of sirolimus have been examined in both the passive 
and active Heymann nephritis model of membranous nephropathy (Cavallo, 1994), but the 
specific effects on podocytes has not been assessed. In a nephrectomized model of passive 
Heyman nephritis, sirolimus reduced the expression of pro-inflammatory and pro-fibrotic 
genes, tubulointerstitial inflammation and fibrosis as well as compensatory renal 
hypertrophy (Bonegio et al., 2005). In the active model, sirolimus exhibited protective effects 
during both the induction as well as the chronic phases (Naumovic et al., 2007). The efficacy 
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of sirolimus in human membranous nephropathy is currently being evaluated in an NIH-
sponsored clinical trial.  
Diabetic kidney disease. Sirolimus is known to prevent the development of diabetes in non-
obese diabetic mouse, which is an autoimmune model of insulin-dependent diabetes, 
presumably due to immunomodulatory effects (Baeder et al., 1992). In the kidney, the 
expression of mTORC1 is upregulated in animals with diabetes, possibly through an 
AMPK-dependent manner (Lee et al., 2007). In addition, several groups have investigated 
the role of sirolimus and mTORC1 in mediating renal injury associated with diabetes. 
These studies showed that sirolimus reduced renal hypertrophy associated with 
hyperglycaemia and that it also has some anti-inflammatory and anti-fibrotic effects 
(Yang et al., 2007, Sataranatarajan et al., 2007, Lee et al., 2007, Sakaguchi et al., 2006, 
Lloberas et al., 2006, Nagai et al., 2005). For example, the treatment of rats with 
streptozotocin (STZ)-induced diabetes with sirolimus from week 16 to 20 reduced 
albuminuria, phosphorylated Akt and mTORC1 expression and growth factor expression 
of TGF-┚1 (Lloberas et al., 2006). These effects were comparable to diabetic animals 
treated with insulin (Lloberas et al., 2006). Sirolimus had similar effects in db/db mice 
with diabetes (Sataranatarajan et al., 2007). The effects of sirolimus in human diabetic 
nephropathy have not been directly evaluated. However, Senior and colleagues reported 
in a retrospective case series, 3 out 62 clinical islet transplant recipients developed 
proteinuria when converted from CNI-based regimen to a CNI-free/sirolimus-based 
treatment (Senior et al., 2005). At least two of the three patients had underlying 
established diabetic nephropathy, which progressed following islet transplantation. 
Another five patients developed microalbuminuria. The proteinuria improved with 
increased doses of CNI, suggesting that the mechanisms of proteinuria may be similar to 
that described for patients with chronic allograft nephropathy (CAN) (i.e. partly due to 
CNI withdrawal) (Senior et al., 2005).  
Chronic kidney disease. In the remnant kidney model in rats and mice, 5/6th   of the kidneys 
are removed either by nephrectomy or infarction through the selective ligation of the renal 
arteries. This model recapitulates some of the features associated with chronic kidney 
progression in humans. In this model, divergent effects of mTOR inhibitors have been 
observed, but this may depend on the timing of their administration, similar to what was 
observed in the glomerular disease models described earlier  (Diekmann et al., 2007, 
Vogelbacher et al., 2007). For example, Vogelbacher and co-workers found that starting 
everolimus three days after induction of the model, suppressed glomerular endothelial and 
mesangial cell proliferation, and worsened structural renal injury and proteinuria 
(Vogelbacher et al., 2007). In contrast, when sirolimus was started at week 6, it improved 
proteinuria, fibrosis and inflammation (Diekmann et al., 2007). Sirolimus attenuated 
glomerular VEGF production in both studies and paradoxically increased serum levels of 
VEGF (Diekmann et al., 2007).  
6.2 Glomerular diseases in which podocyte number increased 
Crescentic glomerulonephritis. mTORC1 may mediate both the immunopathogenesis as well 
as the local glomerular cell proliferation that occurs in crescentic glomerulonephritis. For 
example, in mice the overexpression of HIF-1┙  (Ding et al., 2006). Two recent studies have 
evaluated the effects of sirolimus in murine models of crescentic glomerulonephritis. In 
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mice, prophylactic treatment with sirolimus, 5 days prior to disease induction, decreased the 
proliferation of inflammatory cells and autologous antibody production, but did not alter 
the lymph node expression of CD4+CD25-FoxP3 regulatory cells was detected (Hochegger 
et al., 2008). In contrast, when sirolimus was commenced on day 14 of established disease, 
deleterious effects occurred, including an increase in proteinuria and worsening of 
inflammatory cell infiltration (Hochegger et al., 2008). In rats with crescentic 
glomerulonephritis induced by nephrotoxic serum, treatment with sirolimus during the 
early stage  (1 day after immunization) reduced glomerular cell proliferation, 
tubulointerstitial damage and fibrinoid necrosis, as well as increasing urine volume and 
preventing the decline in renal function (Succar et al., 2007). Of note, the degree of 
histopathological protection following sirolimus treatment was much greater in the 
tubulointerstitial compartment than in the glomerulus, and was associated with reductions 
in both the glomerular and tubulointerstitial phosphorylation of the S6 ribosomal protein 
(Succar et al., 2007).  
HIV-nephropathy. The most common, or "classical", type of HIV-associated nephropathy 
(HIVAN) is a collapsing FSGS, though other forms of kidney disease may also occur with 
HIV (Medapalli, 2011) (Kimmel et al., 2003). Both glomerular and tubular lesions are 
characterized by a proliferative phenotype in HIVAN, and mTORC1 pathway was been 
implicated to contribute to the development of the HIVAN phenotype, as demonstrated in 
Kumar et al., 2010, whereby, renal tissues of transgenic mice showed enhanced 
phosphorylation of p70S6 kinase, 4EBP1 and eIF4B, HIF1-┙, VEGF and an associated 
diminished phosphorylation of eEF2 (Kumar D, 2010). Here transgenic mice receiving 
rapamycin not only showed inhibition of the mTOR-associated downstream signaling but 
also displayed attenuated renal lesions suggesting that the mTOR pathway contributes to 
the HIVAN phenotype and that inhibition of the mTOR pathway can be used as a 
therapeutic strategy to alter the course of HIVAN (Kumar D, 2010). 
7. Therapeutic implications of targeting TORC1 in podocytes in therapy of 
human glomerular diseases 
The foregoing data clearly support that the TORC pathway has an important role in the 
pathogenesis of glomerular disease. However, our knowledge in human disease is in its 
infancy and there remain several significant challenges in translating the known role of 
TORC in podocytes to the therapy of human glomerular disease. Firstly, further studies are 
needed to confirm the expression and functional role of TORC in human disease. Biopsy 
studies of the localization of TORC pathway in glomerular disease are essential. 
Furthermore, serial assessment of biomarkers indication TORC activity will allow the level 
of expression to be determined according to stage of disease. Such assessment may include 
the expression of TORC in podocytes of the urine. Second, further refinements in the way in 
which TORC is modulated in vivo are required. This may require evaluation of low-dose 
sirolimus in conjunction with assessment of biomarkers that modulate the bioactivity of 
TORC; the development of more specific drug-inhibitors that target the TORC pathway as 
well as more specific methods of drug-delivery that target the podocyte. In essence, further 
data in humans is currently lacking and currently essential for furthering the role of TORC 
modulation in podocytes. 
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8. Summary and conclusions 
Podocytes form the final barrier to protein loss, which explains why podocyte injury is 
typically associated with marked proteinuria. Indeed, all forms of glomerular disease are 
characterized by some degree of podocyte abnormality. Recent advancement in the 
understanding of the role of mTOR signalling pathway have emphasized the important role 
this key cell signalling transduction pathway plays in podocyte function both in normal and 
disease conditions. However, much more work is still needed to understand how mTOR 
signalling in podocytes can be modulated to allow the effective therapy of human 
glomerular disease.   
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